|
AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage gastric cancer, compared to chemotherapy alone. The Cambridge, England-based pharmaceutical company said patients were treated with neoadjuvant Imfinzi in combination with chemotherapy before surgery, followed by advujant Imfinzi with chemotherapy and then Imfinzi monotherapy. AstraZeneca said patients treated with the Imfinzi-based regimen before, during and after surgery had a 29% reduction in the risk of disease progression, recurrence or death compared to chemotherapy alone. The results came from a planned interim analysis from the Matterhorn phase 3 trial. ‘This immunotherapy-based perioperative regimen has the potential to change the clinical paradigm in early gastric and gastroesophageal junction cancers based on the reduction in risk of progression, recurrence or death by nearly a third and the strong trend towards improved survival,’ said Cristian Massacesi, chief medical officer & Oncology chief development officer at AstraZeneca. ‘As the third positive trial of perioperative treatment with Imfinzi across multiple tumour types, the Matterhorn trial further validates this approach and highlights our commitment to bringing novel therapies to early stages of disease where there is the greatest chance for cure.’ AstraZeneca shares closed up 2.4% at 10,650.00 pence on Friday in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
